ALZN Alzamend Neuro, Inc.

10

Healthcare [ 3/11 ] | Biotechnology [ 38/157 ]

US | NASDAQ | Stock

Price
$0.425
Decreased by -0.01%
Dollar Volume
93.60 K
ADR%
11.01
Earnings Report Date (estimate)
Mar 15, 23 (N/A)
Market Cap.
40.99 M
Shares Float
67.25 M
Shares Outstanding
96.44 M
Beta
0.00
Price / Earnings
-2.50
BPR
4.71
20D Range
0.31 0.55
50D Range
0.31 0.72
200D Range
0.31 1.50
  • Quarterly Earnings
  • Annual Earnings
Reported Date EPSChange YoY EstimateSurprise
Mar 15, 23 -0.06
Decreased by -100.00%
 -0.04
Decreased by -1.25 K%
Dec 12, 22 -0.03
Increased by +25.00%
 -0.04
Increased by +625.00%
Sep 13, 22 -0.03 -0.07
Increased by +816.33%
Jul 19, 22 -0.04 -0.03
Decreased by -1.11 K%
Mar 15, 22 -0.03 -0.03
Dec 13, 21 -0.04 -0.02
Decreased by -5.00 K%
  • Quarterly Financials
  • Annual Financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Jan 31, 23 0.00
Decreased by N/A%
 -5.43 M
Decreased by -110.88%
Decreased by N/A%
Decreased by N/A%
Oct 31, 22 0.00
Decreased by N/A%
 -3.11 M
Increased by +13.61%
Decreased by N/A%
Decreased by N/A%
Jul 31, 22 0.00
Decreased by N/A%
 -3.04 M
Decreased by -30.92%
Decreased by N/A%
Decreased by N/A%
Apr 30, 22 0.00
Decreased by N/A%
 -3.87 M
Decreased by -207.87%
Decreased by N/A%
Decreased by N/A%
Jan 31, 22 0.00
Decreased by N/A%
 -2.57 M
Decreased by -129.95%
Decreased by N/A%
Decreased by N/A%
Oct 31, 21 0.00
Decreased by N/A%
 -3.60 M
Decreased by -165.85%
Decreased by N/A%
Decreased by N/A%
Jul 31, 21 0.00
Decreased by N/A%
 -2.32 M
Decreased by -76.18%
Decreased by N/A%
Decreased by N/A%
Apr 30, 21 0.00
Decreased by N/A%
 -1.26 M
Decreased by -0.00%
Decreased by N/A%
Decreased by N/A%
  • Top 20 ETF Stock Exposure
  • Top 20 Institutional Holders
  • Top 20 Mutual Fund Holders
Rank ETF Shares Market Value Weight % in ETF
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY

Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001 that is in Phase II clinical trial, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and AL002 that completed preclinical stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.